Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0318937 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2025. Verfasst von Jiali Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bismuth, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evidence-based Traditional Chinese Medicine.
Abstract (Originalsprache)
Background
Currently, quadruple therapy is unanimously recommended as the current first-line treatment option for Helicobacter pylori (H. Pylori) eradication. However, the drug composition of quadruple therapy is very complex, and the efficacy and safety between them is not clear.
Aims
To compare the efficacy and safety of H. Pylori eradication regimens, which were recommended by the Fifth Consensus of China, by network meta-analysis.
Methods
Literature databases were used to retrieve clinical randomized controlled trials of H. Pylori eradication. Network meta-analysis was performed using BUGSnet and meta package of R software, using OR values as effect size, and SUCRA was used to rank the efficacy of interventions under each outcome.
Results
A total of 55 studies and 130 arms were included. The NMA analysis found that the top regimen in term of eradication rate outcome was: Rabeprazole + Bismuth + Furazolidone + Tetracycline (SUCRA, 97.5). In terms of safety outcomes: Lansoprazole + Bismuth + Amoxycillin + Clarithromycin (SUCRA, 91.97).
Conclusions
The bismuth quadruple therapies recommended by the guidelines for the treatment of H. Pylori have good performance in terms of four-week eradication rate and safety outcome indicators, and due to the different resistance of antibiotics in different regional populations, rational use of drugs should be combined with local conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing University of Chinese Medicine, Beijing, China.
- Wang Jing Hospital of CACMS, Beijing, China.
- Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China.
- Center for Evidence-Based Medicine, Beijing University of Chinese Medicine, Beijing, China.
- The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
Förderung
- Evidence-based Traditional Chinese Medicine
Zitieren
APA
Wei, J., Zheng, Z., Wang, X., Jia, B., Sun, M., Wang, J., Wan, Q., Han, M., & Qiu, Y. (2025). Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0318937
Vancouver
Wei J, Zheng Z, Wang X, Jia B, Sun M, Wang J, et al. Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. PLOS ONE. 2025. doi:10.1371/journal.pone.0318937
BibTeX
@article{Wei2025,
author = {Wei, Jiali and Zheng, Zehao and Wang, Xin and Jia, Boyi and Sun, Mingyao and Wang, Jiayi and Wan, Qin and Han, Mei and Qiu, Yue},
title = {Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0318937}
}
EUVIMED